Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer

  • Technology appraisal guidance
  • TA632
  • Published: 

History

Documents created during the development process.

Expected publication

Declaration of interests

Final draft guidance

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators